Health News Releases

September 26, 2024 11:15

Medidata Extends Its Commitment to the Patient Experience with the Launch of Patient Payments

Medidata (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.medidata.com&esheet=54126085&newsitemid=20240925388965&lan=en-US&anchor=Medidata&index=1&md5=2a7f1d88d61b0fe6c85a6c34c7cb

September 26, 2024 10:50

Fujirebio Submits FDA Regulatory Filing for Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease

Fujirebio today announced that its wholly-owned subsidiary Fujirebio Diagnostics, Inc. has filed its Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test with the U.S. Food

September 25, 2024 15:25

Rigaku Holdings Corporation: Approval of Listing on the Tokyo Stock Exchange Prime Market

Rigaku Holdings Corporation, a global solution partner for X-ray analysis (headquarters: Akishima, Tokyo; president and CEO: Jun Kawakami; “Rigaku”), has been approved for a new listing of its shares

September 25, 2024 14:37

EADV 2024 Late Breaking News Sessions: New Galderma Data Demonstrating Nemolizumab’s Long-term Efficacy and Safety in Atopic Dermatitis and Durability in Prurigo Nodularis to Be Shared During Three Oral Presentations

Galderma today announced that it will present new data from the ARCADIA and OLYMPIA clinical trial programs investigating nemolizumab in atopic dermatitis and prurigo nodularis, respectively, at the 2

September 25, 2024 14:10

Aurion Biotech Launches Vyznova® (neltependocel) in Japan for the Treatment of Bullous Keratopathy of the Cornea

Aurion Biotech (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.aurionbiotech.com%2F&esheet=54125897&newsitemid=20240924085009&lan=en-US&anchor=Aurion+Biotech&index=1&md5=0d280e30

September 25, 2024 09:03

Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer

Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=54124287&newsitemid=20240918509211&lan=en-US&anchor=TSE%3A4502%2FNYSE%

September 24, 2024 14:50

Zambon Taps Kinaxis to Enhance Transparency Across Global Supply Chain

Kinaxis® Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.kinaxis.com%2Fen&esheet=54125291&newsitemid=20240923380059&lan=en-US&anchor=Kinaxis%26%23174%3B+Inc.&index=1&md5=23

September 24, 2024 14:40

Kenvue Drives Climate Action Strategy Forward

Kenvue Inc. (NYSE: KVUE) (“Kenvue” or the “Company”), the maker of iconic brands such as Aveeno®, Listerine®, Neutrogena® and Tylenol®, is advancing progress toward the climate change goals outlined i

September 24, 2024 14:00

Neu-REFIX Beta glucan receives rare pediatric disease and orphan drug designations from the US FDA for treatment of Duchenne Muscular Dystrophy

Neu REFIX Beta glucan, made in Japan has received both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (US FDA) for treatment of

September 24, 2024 09:03

Debiopharm Recognizes Groundbreaking Japanese Cancer Research During the 83rd Annual Meeting of the Japanese Cancer Association

Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical company, aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today announced the recognitio

September 20, 2024 17:00

Neuraptive Therapeutics Announces Presentation of Phase 2 Topline Interim Results for NTX-001 at the 2024 American Society for Surgery of the Hand (ASSH) Annual Meeting

Neuraptive Therapeutics Inc., a leading biopharmaceutical company focused on novel treatments for peripheral nerve injuries, today announced that interim topline results from its ongoing Phase 2 NEURO

September 20, 2024 14:20

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, and Dermavant Sciences Ltd. announced today that they have entered into a definit

September 20, 2024 09:49

Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024

Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=54124174&newsitemid=20240919392083&lan=en-US&anchor=TSE%3A4502%2FNYSE%

September 20, 2024 09:45

Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries

Takeda (TOKYO:4502/NYSE: TAK) today committed JPY4.6 billion (Approx. USD 32 million) to five new Global Corporate Social Responsibility (CSR) partners as part of the company’s ongoing commitment to i

September 19, 2024 14:35

Medidata Recognized as a Leader in Everest Group’s Inaugural Electronic Data Capture PEAK Matrix® Assessment

Medidata, a Dassault Systèmes brand and the leading provider of clinical trial solutions to the life sciences industry, has been recognized as a Leader in Everest Group's first-ever PEAK Matrix® Asses

September 18, 2024 15:15

Viromed Medical AG Plans to Acquire All Shares of ActivCell Group AG by Way of a Capital Increase Against Contribution in Kind with Exclusion of Subscription Rights

Viromed Medical AG (Ticker: VMED (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Feqs-cockpit.com%2Fcgi-bin%2Ffncls.ssp%3Ffn%3Dredirect%26url%3D03003d462bf07ae5fbd5a9dd7d755919%26app

September 18, 2024 13:55

Kaitie Kramer Joins Parse Biosciences as Vice President of Marketing

Parse Biosciences (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.parsebiosciences.com%2F&esheet=54122668&newsitemid=20240917957215&lan=en-US&anchor=Parse+Biosciences&index=1&md

September 18, 2024 12:10

Vectura Fertin Pharma, Inc., a Subsidiary of Philip Morris International, Announces Agreement for Sale of Vectura Group to Molex

Vectura Fertin Pharma, Inc., an affiliate of Philip Morris International Inc. (PMI) (NYSE: PM), today announces the sale of its subsidiary Vectura Group Ltd. (Vectura) to Molex Asia Holdings Ltd., and

September 18, 2024 11:45

Galderma Reaffirms Its Leadership in Dermatology With Extensive Presence at EADV 2024

Galderma (SWX:GALD), the pure-play dermatology category leader, announced today it will be showcasing updates from across its industry-leading dermatology portfolio at the 33rd European Academy of Der

September 18, 2024 09:45

Transforming the Future of Medicine with RNA-Based Therapies

Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, ha

September 13, 2024 15:35

MicroVention Rebrands to Terumo Neuro - Reflects Expanded Focus and Strategic Growth

MicroVention, Inc., a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, today announced its official rebranding to Terumo Neuro, effective immediately. Thi

September 13, 2024 14:30

ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-based Radiopharmaceutical Programs Targeting Solid Tumors

ITM Isotope Technologies Munich SE (ITM) (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DknxVWFX97-AJVcLZDmqPUgpwJEhTXICkW7WWecPUpZ99eWRx-Db

September 13, 2024 13:40

Neuraptive Therapeutics Receives FDA Breakthrough Therapy Designation for NTX-001 and Provides Update on the Advancements of NTX-001 for the Treatment of Peripheral Nerve Injury Requiring Repair

Neuraptive Therapeutics, Inc. today announced that NTX-001 has been granted Breakthrough Therapy Designation, thus providing the potential for accelerated development for patients with peripheral nerv

September 13, 2024 11:50

Novotech Unveils 2024 Report on Global Gastric Cancer Clinical Trials and Cutting-Edge Therapeutics